Abstract: The present invention provides a method for isolating RNA including small RNA having a size of 200 nt or less from a sample, comprising the following steps: a) providing a composition comprising RNA and a chaotropic agent; b) adding alcohol; c) incubating the mixture for at least 2 min; d) adding additional alcohol to the mixture to adjust the overall alcohol concentration in the mixture to ?50%; e) binding RNA contained in the mixture to a nucleic acid binding solid phase; f) optionally washing the bound RNA; g) optionally eluting RNA from the solid phase. Due to the step-wise addition of alcohol, the overall RNA yield and the yield of small RNA is improved.

Abstract: Systems acting as logic gates and systems exhibiting quorum sensing are provided, wherein said systems comprise at least one effector nucleic acid origami device, at least one regulator nucleic acid origami device, at least one input and at least one output, and the nucleic acid origami devices are non-immunogenic and/or resistant to nucleases.

Abstract: Contemplated methods and devices are drawn to preparation and analysis of analytes from biological samples. In a preferred embodiment the analytes are nucleic acids that are both released from biological compartments present in the sample and fragmented through the use of a voltage potential applied to a pair of electrodes. The nucleic acids thus prepared are subsequently characterized.

Abstract: Disclosed is a composition which comprises a combination of Aronia extract in an amount of at least about 10 ?g/mg and seleniumin in an amount from about 0.0001 ?g/mg to about 2.0 ?g/mg. The composition may further comprise zinc as additional micronutrient. The composition may be formulated as a pharmaceutical or a nutraceutical composition.

Abstract: Apparatus for biochemical synthesis having a reaction vessel, a temperature control device for the reaction vessel, a plurality of reservoirs for reaction components, and supply/withdrawal systems, e.g. reciprocating syringe pumps and switchable valves. Agitation of a reaction mixture is effected by withdrawing a part of the mixture from the reaction vessel and returning it thereto.

Abstract: This disclosure provides pharmaceutical adenovirus formulations, in particular, liquid pharmaceutical formulations comprising adenoviruses.

Abstract: TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.

Abstract: Disclosed herein is an apparatus comprising: a plurality of locations configured to have probes attached thereto, wherein interaction between the probes and an analyte generates a signal; an optical system comprising a plurality of collimators; a sensor comprising a plurality of pixels configured to detect the signal; wherein the collimators are configured to essentially prevent light from passing if a deviation of a propagation direction of the light from an optical axis of the collimators is greater than a threshold.

Abstract: Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

Abstract: Methods, microfluidic devices, and instruments for magnetic separation of particles from a fluid are described. Examples include microfluidic devices having a removable portion. Examples include microfluidic devices having one or more regions of reduced fluid velocity. Examples further including instruments having pneumatic interfaces. Examples further includes instruments having controllable magnets, imaging components, or combinations thereof.

Abstract: Sensitivity of thin film bulk acoustic resonance (TFBAR) sensors is enhanced by mass amplification and operating a high frequency.

Abstract: The invention relates to new methods of moving helicases past spacers on polynucleotides and controlling the loading of helicases on polynucleotides. The invention also relates to new methods of characterizing target polynucleotides using helicases.

Abstract: The present application relates to methods of detecting a mutation in a target nucleic acid molecule. Two phosphorodiamidate morpholino oligomer probes that differ by at least one base are each covalently coupled to a nano article and hybridized to a target sequence. The melting temperature of the complexes between each of the two probes and the target nucleic acid are measured and compared to determine whether the sample contains a nucleic acid with the mutation. Further, the present invention relates to kits comprising a first and second conjugate as described herein and to the use of such kits for the detection of mutations in a target nucleic acid molecule or for assigning a genotype to a target nucleic acid molecule.

Abstract: Systems, methods and compositions of matter according to the present invention, can be used in capture/enrichment, gene expression profiling and targeted sequencing. Provided are systems, methods and compositions concerning the enhancement of nucleic acid hybridization specificity and controlling the shapes of melting curves revealed by nucleic acid hybrid pairs to optimize nucleic acid analysis. These systems, methods and compositions comprise producing a positively charged surface or surface coating, on the surface of microarray slides or other types of surfaces similarly purposed, which enhances melting curve analysis to the point of allowing detection or differentiation of small changes in sequences between nucleic acid binding partners. The accuracy or resolution of melting curve analysis was to be sufficient to distinguish between the melting of perfect matched dsDNA and dsDNA with the smallest possible change in sequence, a one base pair mismatch.

Abstract: Particular aspects of the present invention provide pharmaceutical compositions comprising isoprenoid-based compounds (e.g., farnesol and/or farnesol analogs or derivatives) or dehydroisoprenoid-based compounds, and novel methods for using same in treating (e.g., suppressing): alcohol withdrawal syndrome and associated neurological symptoms (e.g., depression, tremor, anxiety, autonomic hyperactivity (e.g., sweating, increased blood pressure, tachycardia), hallucinations, alcohol withdrawal seizures, delirium tremens (DT), and memory loss); or for treating in treating convulsive seizure (e.g., epileptic seizure, etc.).

Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.

Abstract: The invention provides methods and systems for ruggedizing a nucleic acid analyzing apparatus. The ruggedized apparatus can be used reliably and effectively in uncontrolled environments, such as, for example at a crime scene to collect and analyze forensic data, as well as in semi-controlled environments, such as, for example at a point of care location.

Abstract: Methods and apparatus for the selection or processing of particles sensitive to the application of an external stimulus to rupture/lysis at least one selected particle or the fusion of first and second selected particles are disclosed herein. Particles are organized using a first field of force by selectively energizing electrodes of an array of selectable electrodes having dimensions comparable to or smaller than those of the particles. A first configuration of stresses is applied to the electrodes; and then a second configuration of stresses is applied to the electrodes, so as to create a second field of force, located substantially close to at least one selected particle to be lysated or to a pair of first and second particles to be fused and such as to produce the application of a stimulus suited to produce their lysis or fusion.

Abstract: A system for detecting electrical properties of a molecular complex is disclosed. The system includes an electrode electrically coupled to a molecular complex that outputs an electrical signal affected by an electrical property of the molecular complex, wherein the effect of the electrical property of the molecular complex on the electrical signal is characterized by an expected bandwidth. The system further includes an integrating amplifier circuit configured to receive the electrical signal from the electrode. The integrating amplifier circuit is further configured to selectively amplify and integrate a portion of the electrical signal over time within a predetermined bandwidth, wherein the predetermined bandwidth is selected at least in part based on the expected bandwidth.

Abstract: Disclosed is a method for determining abnormality in a particle analyzer. The method includes: staining first control particles but not staining second control particles which emit fluorescence; irradiating with light the first control particles and the second control particles flowing in a flow cell, and detecting fluorescence from the first control particles and the second control particles; obtaining a first management value indicating a detection result of the fluorescence emitted from the first control particles and a second management value indicating a detection result of the fluorescence emitted from the second control particles; and determining abnormality in the staining step, based on a value calculated from the first management value and the second management value or a ratio between the first management value and the second management value.